Head to head
Tirzepatide vs Retatrutide
Two compounds, one grading system.
On human evidence, Tirzepatide currently leads: fda approved versus well researched.
01
At a glance
TirzepatideFDA approved
Dual GIP/GLP-1 agonist. Approved, and outperformed semaglutide in head-to-head trials.
7,505publications
210RCTs
RetatrutideWell researched
Triple agonist with the strongest phase 2 weight results yet — but not approved anywhere.
927publications
18RCTs
02
Side by side
| Attribute | Tirzepatide | Retatrutide |
|---|---|---|
| Goal | Metabolic & fat loss | Metabolic & fat loss |
| Evidence | FDA approved | Well researched |
| Publications | 7,505 | 927 |
| Randomised trials | 210 | 18 |
| Sport (WADA) | not listed | S0 — prohibited |
| US compounding | — | — |
03
Claims vs data
Tirzepatide — claims vs data
| Greater average weight loss than semaglutide | supported |
| Requires no medical supervision | overreach |
Retatrutide — claims vs data
| Largest weight loss of any trialled agent to date | partially true |
| Approved and available | overreach |